Solid Biosciences Added to the Nasdaq Biotechnology Index
Solid Biosciences (Nasdaq: SLDB), a life sciences company focused on precision genetic medicines for neuromuscular and cardiac diseases, has been added to the Nasdaq Biotechnology Index庐 (NBI) effective December 23, 2024. The NBI tracks performance of biotechnology and pharmaceutical securities listed on Nasdaq, using a modified capitalization-weighted methodology. Companies must meet specific eligibility criteria including minimum market capitalization, daily trading volume, and public company seasoning requirements. Index constituents are selected annually in December.
Solid Biosciences (Nasdaq: SLDB), un'azienda delle scienze della vita focalizzata su medicine genetiche di precisione per malattie neuromuscolari e cardiache, 猫 stata aggiunta all'indice Nasdaq Biotechnology庐 (NBI) con effetto dal 23 dicembre 2024. L'NBI monitora le performance delle titoli biotecnologici e farmaceutici quotati su Nasdaq, utilizzando una metodologia di capitalizzazione ponderata modificata. Le aziende devono soddisfare specifici criteri di idoneit脿, inclusa la capitalizzazione di mercato minima, il volume di scambi giornaliero e i requisiti di esperienza come societ脿 pubblica. I componenti dell'indice sono selezionati annualmente a dicembre.
Solid Biosciences (Nasdaq: SLDB), una empresa de ciencias de la vida centrada en medicamentos gen茅ticos de precisi贸n para enfermedades neuromusculares y card铆acas, ha sido agregada al 铆ndice Nasdaq Biotechnology庐 (NBI) a partir del 23 de diciembre de 2024. El NBI rastrea el rendimiento de valores biotecnol贸gicos y farmac茅uticos listados en Nasdaq, utilizando una metodolog铆a de capitalizaci贸n ponderada modificada. Las empresas deben cumplir criterios espec铆ficos de elegibilidad, incluidos una capitalizaci贸n de mercado m铆nima, volumen diario de negociaci贸n y requisitos de experiencia como empresa p煤blica. Los componentes del 铆ndice se seleccionan anualmente en diciembre.
靻旊Μ霌� 氚旍澊鞓れ偓鞚挫柛鞀� (Nasdaq: SLDB)鞚� 鞁犼步攴检湣 氚� 鞁灔 歆堧硲鞚� 鞙勴暅 鞝曤皜 鞙犾爠 鞚橃暯頀堨棎 欤茧牓頃橂姅 靸濍獏 瓿柬暀 須岇偓搿�, 2024雲� 12鞗� 23鞚茧秬搿� 雮橃姢雼� 靸濍獏瓿淀暀 歆�靾�(NBI)鞐� 於旉皜霅橃棃鞀惦媹雼�. NBI電� 雮橃姢雼レ棎 靸侅灔霅� 靸濍獏瓿淀暀 氚� 鞝滌暯 歃濌秾鞚� 靹标臣毳� 於旍爜頃橂┌, 靾橃爼霅� 鞁滉皜 齑濎暋 臧�欷� 氚╇矔搿犾潉 靷毄頃╇媹雼�. 旮办梾鞚� 斓滌唽 鞁滉皜 齑濎暋, 鞚检澕 瓯半灅霟�, 瓿店皽 旮办梾 瓴诫牓 鞖旉贝鞚� 韽暔頃� 韸轨爼 鞝侁博靹� 旮办鞚� 於╈”頃挫暭 頃╇媹雼�. 歆�靾� 甑劚 鞖旍唽電� 毵る厔 12鞗旍棎 靹犿儩霅╇媹雼�.
Solid Biosciences (Nasdaq: SLDB), une entreprise de sciences de la vie ax茅e sur des m茅dicaments g茅n茅tiques de pr茅cision pour les maladies neuromusculaires et cardiaques, a 茅t茅 ajout茅e 脿 l'indice Nasdaq Biotechnology庐 (NBI) en date du 23 d茅cembre 2024. Le NBI suit la performance des valeurs biotechnologiques et pharmaceutiques list茅es sur le Nasdaq, 脿 l'aide d'une m茅thodologie de capitalisation boursi猫re modifi茅e. Les entreprises doivent r茅pondre 脿 des crit猫res d'茅ligibilit茅 sp茅cifiques incluant une capitalisation boursi猫re minimale, un volume de n茅gociation quotidien, et des exigences de long茅vit茅 en tant qu'entreprise publique. Les composants de l'indice sont s茅lectionn茅s chaque ann茅e en d茅cembre.
Solid Biosciences (Nasdaq: SLDB), ein Unternehmen im Bereich der Lebenswissenschaften, das sich auf pr盲zise genetische Arzneimittel f眉r muskuloskelettale und kardiovaskul盲re Erkrankungen konzentriert, wurde zum Nasdaq Biotechnology Index庐 (NBI) ab dem 23. Dezember 2024 hinzugef眉gt. Der NBI verfolgt die Performance von Biotechnologie- und Pharmawerten, die an der Nasdaq gelistet sind, unter Verwendung einer modifizierten kapitalisierungsgewichteten Methodik. Unternehmen m眉ssen spezifische Zulassungskriterien erf眉llen, einschlie脽lich einer minimalen Marktkapitalisierung, eines t盲glichen Handelsvolumens und der Anforderungen an die 枚ffentliche Unternehmensreife. Die Indexbestandteile werden j盲hrlich im Dezember ausgew盲hlt.
- Addition to Nasdaq Biotechnology Index increases visibility and potential institutional investment exposure
- Company meets minimum market cap and trading volume requirements for index inclusion
- None.
CHARLESTOWN, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the 鈥淐ompany鈥� or 鈥淪olid鈥�), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it was added to the Nasdaq Biotechnology Index庐 (Nasdaq: NBI) effective prior to the market open on Monday, December 23, 2024.
The Nasdaq Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market庐 (Nasdaq庐) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NBI is calculated under a modified capitalization-weighted methodology. Companies in the NBI must meet eligibility requirements, including minimum market capitalization, average daily trading volume, and seasoning as a public company, among other criteria. Nasdaq selects constituents once annually in December.
For more information about the Nasdaq Biotechnology Index, please visit .
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid鈥檚 mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit .
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
Media Contact:
Glenn Silver
FINN Partners
FAQ
When was Solid Biosciences (SLDB) added to the Nasdaq Biotechnology Index?
What are the requirements for joining the Nasdaq Biotechnology Index that SLDB met?
How often does the Nasdaq Biotechnology Index update its constituents?
What type of weighting methodology does the NBI use for stocks like SLDB?
